Your browser doesn't support javascript.
loading
Treatment Patterns Among Patients with Metastatic and/or Unresectable Gastric Cancer in Brazil.
de Alencar Camara Vieira, Fernando Meton; de Souza Victorino, Ana Paula Ornellas; de Iracema Gomes Cubero, Daniel; Beato, Carlos Augusto de Mendonça; Minowa, Eimy; Julian, Guilherme Silva; Novick, Diego.
Afiliação
  • de Alencar Camara Vieira FM; Instituto COI de Educação e Pesquisa, Rio de Janeiro, Brazil.
  • de Souza Victorino APO; Instituto Nacional de Câncer José Alencar Gomes da Silva, Rio de Janeiro, Brazil.
  • de Iracema Gomes Cubero D; Centro de Estudos e Pesquisas de Hematologia e Oncologia/FM ABC, Santo André, Brazil.
  • Beato CAM; Fundação Amaral Carvalho, Jaú, Brazil.
  • Minowa E; Evidências-Kantar Health, São Paulo, Brazil.
  • Julian GS; Evidências-Kantar Health, São Paulo, Brazil.
  • Novick D; Lilly Research Centre, Eli Lilly and Company, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20 6PH, UK. novick_diego@lilly.com.
J Gastrointest Cancer ; 50(4): 780-793, 2019 Dec.
Article em En | MEDLINE | ID: mdl-30078125
ABSTRACT

PURPOSE:

In Brazil, patients with gastric cancer have not been systematically followed-up and evaluated, thus data regarding patterns of care and outcomes are scarce or missing. The objective of this study was to evaluate patterns of care of advanced gastric cancer in standard practice in Brazil.

METHODS:

This was an observational, multicenter, retrospective study, which included patients with metastatic and/or unresectable gastric cancer (MGC) who underwent at least one line of treatment.

RESULTS:

We analyzed data on 155 patients diagnosed with MGC, most are men (57.4%), with mean age of 61.9 years at diagnosis, with 99 (63.9%) from the public healthcare system and 56 (36.1%) from the private setting. Platinum- and/or fluoropyrimidine-containing regimens prevailed as first-line therapy, while irinotecan was the most used regimen in the second and in the third lines. More than 40% of patients underwent only one line of systemic therapy, of which around 40% either died during the treatment or went on to best supportive care (BSC) only. The remaining patients received further treatment lines. A fifth of the patients in the study died within two months after discontinuation of the first-line treatment. Adverse events, use of concomitant medications, support procedures, outpatient visits, and hospitalizations were reported for most patients, especially in the first and second lines of treatment and during exclusive BSC.

CONCLUSIONS:

Survival during or after the first-line chemotherapy remains poor among patients with MGC. Adverse events and health resource use were common in the first and second lines of treatment and in exclusive BSC. These results suggest that there is space for improvement in the treatment of MGC in Brazil.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cuidados Paliativos / Neoplasias Gástricas / Padrões de Prática Médica / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cuidados Paliativos / Neoplasias Gástricas / Padrões de Prática Médica / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2019 Tipo de documento: Article